Biomedtracker: 開発中医薬品をFDA承認確率で評価

2021 Clinical Development Success Rates

This is both an updated study of clinical drug development success rates from our 2016 report, and an expansion into the drivers of success with the addition of machine learning modeling to analyze the predictive factors contributing to drug development.

Citeline

Exploring Basket and Umbrella Oncology Trials

To increase flexibility and efficiency in drug development, master protocols have emerged as an innovative clinical trial design, including basket and umbrella trials. Learn more about how these approaches are being used within oncology research through an overview of the clinical landscape, trial outcomes and trends.

Depression New Insights Shifting the Treatment Paradigm Whitepaper

Depression affects approximately 1 in 6 Americans, with 10 – 30% of depression patients becoming treatment-resistant. Find out what the pipeline looks like for depression and what the emerging strategies in this area are. This data-packed whitepaper from Informa Pharma Intelligence can now be downloaded – free.

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

Curing What Hinders Alzheimer’s Drug Development

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

Citeline

Clinical Trials State of the Industry Report 2019

KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables. The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Remdesivir Licensing Agreements for Generics Companies

Keep up with crucial developments in the generics industry as Gilead signs non-exclusive, voluntary licensing agreements with several generics manufacturers in an effort to more widely manufacture and distribute the COVID-19 drug remdesivir, used to help patients recover from severe coronavirus infections faster.

Pharmaprojects: 医薬品開発パイプラインのデータベース

世界の医薬品R&D最新動向・ホワイトペーパー

世界の医薬品産業における研究開発トレンドを検証する年次ホワイトペーパー『Pharma R&D Annual Review 2020』が発行されました。1980年以来、弊社が追跡してきた世界の医薬品情報の蓄積を駆使して、会社別、治療領域別、疾病別、標的および剤型別にパイプラインを検証し、業界トレンドを評価しました。

Pharmaprojects: 医薬品開発パイプラインのデータベース

Pharma R&D Annual Review 2020 ウェビナー

世界の医薬品産業におけるR&Dトレンドを検証するホワイトペーパー『Pharma R&D Annual Review 2020』からポイントをピックアップして、執筆者のイアン・ロイドがオンラインセミナーを行いました（2020年4月28日）。新たな10年の幕開けとともにR&Dはどこへ向かうのでしょうか。Pharmaprojectsのデータ粒度の向上を受けて、今年は新たに様々な分析を実施し、これまで以上に深くパイプラインを掘り下げています。